natap.org

Back&nbsp Merck's LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia At week 24 in the CORALreef Lipids and CORALreef HeFH trials, LIPFENDRA significantly reduced LDL-C by a placebo-adjusted 56% and 59%, respectively LIPFENDRA is a novel macrocyclic peptide that binds to PCSK9 and inhibits the interaction of PCSK9 with LDL receptors RAHWAY, N.J., July 16, 2026 - Merck (NYSE: MRK), known as...

AIDS Sept 2026 Download the PDF here Download the PDF here Discussion In this prospective multicenter cohort of MSM with HIV in Madrid (2022–2024), conducted in a context of broad access to DAAs and during a period when DoxyPEP was not implemented, three data-driven phenotypes stratified 12-month incidence of ARHCV and bacterial STIs. ARHCV incidence was concentrated in the phenotype characterized by high-intensity chemsex and practices associated with rectal mucosal trauma, whereas bacterial...

Back&nbsp Distinct associations of peripheral mtDNA copy number and bioenergetic function with cognition in women with HIV and psychiatric comorbidities AIDS Aug 2026 Download the PDF here Download the PDF here Discussion This study provides evidence that distinct peripheral mitochondrial markers are differentially associated with cognitive performance in virally suppressed WWH with cognitive impairment.

Back&nbsp Long-term effectiveness of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV and resistance-associated mutations AIDS Oct 2026 Download the PDF here Resistance-associated mutations (RAMs) limit treatment options for HIV. We evaluated virologic outcomes in people with HIV harboring RAMs who switched to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in a real-world cohort during 4 years of follow-up.

Download the PDF here Our findings further support the concept that ageing is accompanied by an increasing burden of chronic diseases and medication use, emphasizing the need for comprehensive management of multimorbidity in older people living with HIV. Each one-year increase in age was associated with an approximate 4.1% increase in the expected number of comorbid conditions and a 3.4% increase in the expected number of medications used (Table 4).

High rates of virological resuppression after treatment interruption among people living with HIV restarting bictegravir-based therapy: a real-world cohort study IAS 2026 Rio Brazil July 26-31

13th IAS Conference on HIV Science IAS 2026 July 26-31 Rio, Brazil Back Initial HIV Therapy for Adults and Treatment-Associated Weight Gain-The Opti-DOR Randomized Clinical Trial July 31, 2026 Download the PDF here Key Points Question Among adults with HIV at risk of treatment-associated weight gain, does an alternative first-line regimen produce less weight gain than treatment combinations containing an integrase strand transfer inhibitor (eg, dolutegravir or bictegravir) along with...

U.S. FDA Approves Gilead’s Bixlenvo™, A New Once-Daily Single Tablet Option For Virologically Suppressed Adults With HIV, Including Those On Complex Regimens - (08/27/26) CROI2026: Switch to BIC + LEN in Virologically Suppressed People With HIV on Complex Regimens: Week 96 Outcomes CROI2026: Phase 3 Efficacy and Safety of Switch From Complex Regimen to Single-Tablet BIC/LEN in ARTISTRY-1 CROI2026: Phase 3 Efficacy and Safety of Switch From B/F/TAF to Single-Tablet BIC/LEN in ARTISTRY-2...

Back&nbsp One Dose CVD Treatment Early Research In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemi: one dose heart disease treatment May 25, 2026 Download the PDF here Download the PDF here Conclusions One dose of VERVE-102 led to dose-dependent, substantial, and sustained reductions in PCSK9 and LDL cholesterol levels.

Back&nbsp U.S. FDA Approves Gilead’s Bixlenvo™, A New Once-Daily Single Tablet Option For Virologically Suppressed Adults With HIV, Including Those On Complex Regimens August 27, 2026 U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens – Novel Daily Oral Tablet Combines Bictegravir, a Guideline-Recommended INSTI with a High Barrier to Resistance, with Lenacapavir, a First-in-Class Capsid...